Sensus Healthcare (NASDAQ:SRTS) Given “Buy” Rating at Maxim Group

Sensus Healthcare (NASDAQ:SRTSGet Rating)‘s stock had its “buy” rating restated by investment analysts at Maxim Group in a report released on Friday, TipRanks reports. They presently have a $14.00 price objective on the stock. Maxim Group’s price objective indicates a potential upside of 79.49% from the company’s previous close.

A number of other equities research analysts also recently commented on the company. Zacks Investment Research downgraded Sensus Healthcare from a “buy” rating to a “hold” rating in a research report on Tuesday. HC Wainwright boosted their price objective on Sensus Healthcare from $12.00 to $13.00 and gave the stock a “buy” rating in a research note on Thursday, March 3rd. Finally, TheStreet upgraded Sensus Healthcare from a “c” rating to a “b-” rating in a research note on Friday, February 11th.

Sensus Healthcare stock traded up $0.64 during mid-day trading on Friday, reaching $7.80. 528,174 shares of the company were exchanged, compared to its average volume of 216,376. Sensus Healthcare has a twelve month low of $3.08 and a twelve month high of $11.96. The firm’s 50-day simple moving average is $9.39 and its two-hundred day simple moving average is $7.92. The firm has a market cap of $130.10 million, a PE ratio of 6.09 and a beta of 0.52.

Sensus Healthcare (NASDAQ:SRTSGet Rating) last posted its quarterly earnings results on Thursday, May 5th. The company reported $0.97 EPS for the quarter, beating the consensus estimate of $0.06 by $0.91. Sensus Healthcare had a return on equity of 18.88% and a net margin of 15.23%. During the same period in the previous year, the company posted ($0.07) earnings per share. Sell-side analysts predict that Sensus Healthcare will post 0.3 EPS for the current fiscal year.

In other news, COO Nicolas Soro sold 10,000 shares of the company’s stock in a transaction on Wednesday, March 9th. The shares were sold at an average price of $10.20, for a total value of $102,000.00. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Joseph C. Sardano sold 44,782 shares of the company’s stock in a transaction on Friday, March 11th. The stock was sold at an average price of $10.11, for a total transaction of $452,746.02. The disclosure for this sale can be found here. Insiders sold 114,056 shares of company stock valued at $1,151,818 over the last 90 days. 24.30% of the stock is currently owned by insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of SRTS. Morgan Stanley increased its stake in shares of Sensus Healthcare by 340.4% in the first quarter. Morgan Stanley now owns 44,894 shares of the company’s stock worth $172,000 after acquiring an additional 34,699 shares during the last quarter. Northwestern Mutual Wealth Management Co. boosted its holdings in Sensus Healthcare by 83.3% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 5,500 shares of the company’s stock worth $40,000 after purchasing an additional 2,500 shares in the last quarter. HCR Wealth Advisors bought a new stake in Sensus Healthcare in the fourth quarter worth $72,000. Dimensional Fund Advisors LP boosted its holdings in Sensus Healthcare by 47.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 68,298 shares of the company’s stock worth $493,000 after purchasing an additional 22,015 shares in the last quarter. Finally, Acadian Asset Management LLC bought a new stake in Sensus Healthcare in the fourth quarter worth $791,000. 20.49% of the stock is currently owned by institutional investors and hedge funds.

Sensus Healthcare Company Profile (Get Rating)

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy (SRT), a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a SRT-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.

Recommended Stories

Receive News & Ratings for Sensus Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensus Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.